Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 11/20 | 0.79 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.79 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.79 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.79 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.79 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.79 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.79 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.79 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.79 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | CASP7 | P55210 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18575735 | 1.00 | GPBAR1 (0.79) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| SCHEMBL13988211 | 1.00 | GPBAR1 (0.79) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| SCHEMBL7711337 | 1.00 | GPBAR1 (0.79) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| SCHEMBL19444905 | 1.00 | GPBAR1 (0.79) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| SCHEMBL14092766 | 1.00 | GPBAR1 (0.79) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| SCHEMBL13988803 | 1.00 | GPBAR1 (0.79) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| SCHEMBL4998834 | 1.00 | GPBAR1 (0.79) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| SCHEMBL7991006 | 0.91 | GPBAR1 (0.72) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL25023120 | 0.88 | GPBAR1 (1.00) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL18200112 | 0.88 | GPBAR1 (1.00) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4171352-A | Quantitative evaluation of enteric microbial overgrowth | POLYSCIENCES, INC. (US) | 1979-10-16 | — | — | US | claimed |
| US-10000526-B2 | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size | DR. FALK PHARMA GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-20170057990-A1 | Optimized Synthesis Of Pure, Non-Polymorphic, Crystalline Bile Acids With Defined Particle Size | DR. FALK PHARMA GMBH (DE) | 2017-03-02 | — | — | US | disclosed |
| US-9512167-B2 | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size | DR. FALK PHARMA GMBH (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20140050791-A1 | Optimized Synthesis Of Pure, Non-Polymorphic, Crystalline Bile Acids With Defined Particle Size | DR. FALK PHARMA GMBH (DE) | 2014-02-20 | — | — | US | disclosed |
| EP-2646457-A1 | OPTIMIZED SYNTHESIS OF PURE, NON-POLYMORPHIC, CRYSTALLINE BILE ACIDS WITH DEFINED PARTICLE SIZE | Dr. Falk Pharma Gmbh (DE) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012072689-A1 | OPTIMIZED SYNTHESIS OF PURE, NON-POLYMORPHIC, CRYSTALLINE BILE ACIDS WITH DEFINED PARTICLE SIZE | DR. FALK PHARMA GMBH (DE) | 2012-06-07 | — | — | WO | disclosed |
| US-7601708-B2 | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | XENOPORT, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080171729-A1 | Use Of A Steroid For Enhancement Of Skin Permeability | NOVARTIS AG | 2008-07-17 | — | — | US | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| EP-1773336-A1 | USE OF A STEROID FOR ENHANCEMENT OF SKIN PERMEABILITY | Novartis AG (CH) | 2007-04-18 | — | — | EP | disclosed |
| US-7147859-B2 | Application of phytosterols (and their isomers), folic acid, cyanocobalamin and pyridoxin in dietetic (alimentary) fibers | LABORATORIOS BIOSINTETICA LTDA. (BR) | 2006-12-12 | — | — | US | disclosed |
| WO-2006008092-A1 | USE OF A STEROID FOR ENHANCEMENT OF SKIN PERMEABILITY | NOVARTIS AG (CH) | 2006-01-26 | — | — | WO | disclosed |
| US-20050272710-A1 | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | XENOPORT, INC. (US) | 2005-12-08 | — | — | US | disclosed |
| EP-1343805-A4 | BILE-ACID DERIVED COMPOUNDS FOR PROVIDING SUSTAINED SYSTEMIC CONCENTRATIONS OF DRUGS AFTER ORAL ADMINISTRATION | XENOPORT INC (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1343805-A1 | BILE-ACID DERIVED COMPOUNDS FOR PROVIDING SUSTAINED SYSTEMIC CONCENTRATIONS OF DRUGS AFTER ORAL ADMINISTRATION | Xenoport, Inc. (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002028881-A1 | BILE-ACID DERIVED COMPOUNDS FOR PROVIDING SUSTAINED SYSTEMIC CONCENTRATIONS OF DRUGS AFTER ORAL ADMINISTRATION | XENOPORT, INC. (US) | 2002-04-11 | — | — | WO | disclosed |
| US-4460509-A | STEROIDS WITH HETERO RING SIDE CHAIN | BETH ISRAEL MEDICAL CENTER (US) | 1984-07-17 | — | — | US | disclosed |
| US-4171352-A | Quantitative evaluation of enteric microbial overgrowth | POLYSCIENCES, INC. (US) | 1979-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057990-A1 | Optimized Synthesis Of Pure, Non-Polymorphic, Crystalline Bile Acids With Defined Particle Size | SLC10A1, ABCB11, NR1H4 | GPBAR1 8/4885EPHA2 2402/4885HSD17B10 164/4885 |
| US-20140050791-A1 | Optimized Synthesis Of Pure, Non-Polymorphic, Crystalline Bile Acids With Defined Particle Size | SLC10A1, ABCB11, NR1H4 | GPBAR1 8/4885EPHA2 2456/4885HSD17B10 169/4885 |
| US-10000526-B2 | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size | SLC10A1, ABCB11, NR1H4 | GPBAR1 8/4885EPHA2 2402/4885HSD17B10 164/4885 |
| US-20080171729-A1 | Use Of A Steroid For Enhancement Of Skin Permeability | SERPINA6, CYP11A1, HSD17B7 | GPBAR1 260/4885EPHA2 1668/4885HSD17B10 315/4885 |
| US-20050272710-A1 | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | SLC10A2, SLC10A1, ABCB11 | GPBAR1 5/4885EPHA2 875/4885HSD17B10 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.